Browse the evidence

Preoperative use of GLP-1 receptor agonists is not significantly associated with the odds of postoperative aspiration pneumonia.

Clinicians may reconsider the necessity of withholding GLP-1 RAs preoperatively based on these findings.

Patients using GLP-1 receptor agonists are more likely to be female and diagnosed with both obesity and diabetes compared to nonusers.

Understanding the demographics of GLP-1 RA users can inform targeted interventions and education.

Trials with both smartphone and in-person components exhibited the highest racial minority enrollment.

Combining technology with in-person interactions may further improve minority enrollment in weight loss trials.

Many racial and ethnic minority groups are under-represented in clinical trials of behavioral weight loss treatment.

Recognizing the under-representation of minorities can guide efforts to improve enrollment in clinical trials.

The results of the analysis should be interpreted with caution due to the minority representation of BPD and mini-GBP among bariatric surgeries.

Practitioners should be aware of the limitations in the data when recommending surgical options.

Further research with larger sample sizes is needed to confirm these results.

Practitioners should be aware that current findings are preliminary and require further validation.

The number of people living with obesity has tripled worldwide since 1975.

Public health initiatives should address the rising obesity rates.

No dietary intervention was introduced during the experimental period.

The findings are solely attributed to the exercise intervention, emphasizing its effectiveness without dietary influence.

Higher sustained pharmacy costs were the main driver of the cost difference favoring MBS over GLP-1 receptor agonists.

Healthcare providers should consider ongoing medication costs when recommending obesity treatments.

Restrictive diets such as very-low-carb, ketogenic, very-low-calorie diets, and intermittent fasting have scarce evidence for direct benefit to NAFLD.

Practitioners should be cautious in recommending restrictive diets for NAFLD due to insufficient evidence of their benefits.

The random forest classification algorithm exhibits superior accuracy rates of 97% for Obesity_Type_I, 99% for Obesity_Type_II, and 83% for Obesity_Type_III compared to alternative classifiers.

Practitioners can utilize machine learning algorithms, particularly random forests, for more accurate obesity classification.

The study demonstrates the efficacy of machine learning methodologies in forecasting different forms of obesity.

Machine learning can be a powerful tool for predicting obesity, aiding in prevention and management strategies.

Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.

Clinicians may consider semaglutide as the preferred option over tirzepatide for this patient population.

The number of adults with diabetes globally increased from 108 million in 1980 to 422 million in 2014.

Healthcare practitioners should be aware of the significant increase in diabetes prevalence when planning interventions.

Worldwide age-standardized adult diabetes prevalence doubled from 4.3% to 9.0% in men and from 5.0% to 7.9% in women.

This information is crucial for public health initiatives targeting diabetes prevention and management.

Few companies in the US reduced portion sizes of ultra-processed foods since 2002.

Practitioners should be aware that portion sizes of ultra-processed foods have not decreased significantly, which may impact dietary recommendations.

The safety of retatrutide needs to be determined in larger and longer trials.

Practitioners should be aware that more extensive safety data is needed before fully endorsing retatrutide.

The incidence of completed or attempted suicide and occurrences of suicidal ideation or self-harm is very low in individuals receiving GLP-1 receptor agonists (0.047 per 100 person-years) compared to placebo (0.042 per 100 person-years), with no statistically significant difference.

Practitioners can be reassured that GLP-1 RAs do not appear to increase the risk of suicidality in their patients.

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.

Healthcare providers can continue to prescribe GLP-1 RAs without heightened concern for suicidality in clinical settings.

Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.

Practitioners should be aware of the significant projected costs associated with GLP-1RA coverage under Medicare.

The net increased spending due to expanded Medicare coverage for GLP-1RAs is projected to be $47.7 billion over 10 years.

Practitioners should be aware of the substantial net spending implications of GLP-1RA coverage.

No association was found with other disorders of the optic nerve or visual pathways.

Other optic nerve or visual pathway disorders are not linked to semaglutide or tirzepatide use.

There is a need to end disparities in cardiovascular morbidity and mortality related to race, sex, and income inequality.

Healthcare systems should implement strategies to reduce these disparities.

Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).

Semaglutide can be considered safe regarding eye disorders and diabetic retinopathy.